A new study published by the Journal of Clinical Pathways demonstrates significant cost-savings generated by Sandoz’s pegfilgrastim biosimilar Ziextenzo®.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Jul 24, 2020
A new study published by the Journal of Clinical Pathways demonstrates significant cost-savings generated by Sandoz’s pegfilgrastim biosimilar Ziextenzo®.
By Bioblast Editor | Jul 23, 2020
The CHMP adopts a positive opinion recommending the granting of marketing authorisation for Centus Biotherapeutics’ Equidacent® (biosimilar bevacizumab) for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, epithelial ovaria...
By Bioblast Editor | Jul 22, 2020
Biogen released its Q2 FY20 financial results, reporting a 7% decrease in biosimilar revenues compared to FY19.
By Bioblast Editor | Jul 22, 2020
Cadila Pharma announces it has launched Bevaro® (biosimilar bevacizumab) in India. Bevaro® s indicated for ovarian cancer, glioblastoma, colorectal cancer, breast cancer, lung cancer, cervical cancer and kidney cancer.
By Bioblast Editor | Jul 22, 2020
Genentech publishes the results from its Ph III Archway study, evaluating its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD). Genentech reported that 98.4% of patients were able to go six months without ...
By Bioblast Editor | Jul 21, 2020
Novartis releases its Q2 FY20 financial results, reporting COVID-19 negatively impacted demand for Lucentis® (ranibizumab).
By Naomi Pearce | Jul 20, 2020
Significant biosimilar activities this week include
09 Jul 20 | AU | The Australian Generic and Biosimilar Medicines Association (GBMA) announced it reached over 540,000 Australians in its Biosimilar Awareness Week, which was held digitally May 25-29.
14 Jul 20 ...
By Bioblast Editor | Jul 20, 2020
AstraZeneca announced interim results from ongoing Ph I/II trial showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
By Bioblast Editor | Jul 20, 2020
Spherix reports that the EU market for AbbVie’s Humira® has been negatively impacted by gastroenterologists increasingly prescribing alternative mechanism of action agents, including Stelara® (ustekinumab) and Entyvio® (vedolizumab) for ulcerative colitis (UC) and Cro...
By Bioblast Editor | Jul 17, 2020
VentureTECH, Duopharma and PanGen Biotech announce a joint venture to develop a Malaysian biosimilar production facility.
SUBSCRIBE TO PEARCE IP